These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26583620)

  • 1. Outcomes of Patients With Relapsed Hepatoblastoma Enrolled on Children's Oncology Group (COG) Phase I and II Studies.
    Trobaugh-Lotrario AD; Meyers RL; Feusner JH
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):187-90. PubMed ID: 26583620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
    Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
    Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group.
    Van Tornout JM; Buckley JD; Quinn JJ; Feusner JH; Krailo MD; King DR; Hammond GD; Ortega JA
    J Clin Oncol; 1997 Mar; 15(3):1190-7. PubMed ID: 9060563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapsed hepatoblastoma.
    Trobaugh-Lotrario AD; Feusner JH
    Pediatr Blood Cancer; 2012 Nov; 59(5):813-7. PubMed ID: 22648963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary study on the efficacy of irinotecan in the treatment of childhood relapsed hepatoblastoma].
    Chang J; Zhang YT; Zhong XD; Wang LZ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):588-90. PubMed ID: 23866285
    [No Abstract]   [Full Text] [Related]  

  • 6. Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.
    Ijichi O; Ishikawa S; Shinkoda Y; Tanabe T; Okamoto Y; Takamatsu H; Inomata Y; Kawano Y
    Pediatr Transplant; 2006 Aug; 10(5):635-8. PubMed ID: 16857004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group.
    Meyers RL; Rowland JR; Krailo M; Chen Z; Katzenstein HM; Malogolowkin MH
    Pediatr Blood Cancer; 2009 Dec; 53(6):1016-22. PubMed ID: 19588519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma.
    George SL; Broster S; Chisholm JC; Brock P
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):e295-7. PubMed ID: 22469940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival after liver transplantation for hepatoblastoma: a 2-center experience.
    Browne M; Sher D; Grant D; Deluca E; Alonso E; Whitington PF; Superina RA
    J Pediatr Surg; 2008 Nov; 43(11):1973-81. PubMed ID: 18970927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal and neonatal hepatic tumors.
    Isaacs H
    J Pediatr Surg; 2007 Nov; 42(11):1797-803. PubMed ID: 18022426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical observation on the treatment outcome of 14 children with hepatoblastoma in a single medical center].
    Pan C; Tang JY; Chen J; Xue HL; Dong L; Zhou M; Jiang H; Ye QD; Gu LJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Aug; 11(8):659-62. PubMed ID: 19695195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma.
    Meyers RL; Katzenstein HM; Krailo M; McGahren ED; Malogolowkin MH
    J Pediatr Surg; 2007 Dec; 42(12):2050-6. PubMed ID: 18082706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoblastoma clinical research: lessons learned and future challenges.
    Perilongo G; Malogolowkin M; Feusner J
    Pediatr Blood Cancer; 2012 Nov; 59(5):818-21. PubMed ID: 22678761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of alpha-fetoprotein secreting hepatoblastoma by response of serum alpha-fetoprotein levels: a new concept.
    Sayar D; Yaniv I; Goshen Y; Cohen IJ
    Pediatr Hematol Oncol; 2001 Dec; 18(8):509-18. PubMed ID: 11764100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
    Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
    Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94.
    Fuchs J; Bode U; von Schweinitz D; Weinel P; Erttmann R; Harms D; Mildenberger H
    Klin Padiatr; 1999; 211(4):305-9. PubMed ID: 10472567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma.
    Warmann SW; Heitmann H; Teichmann B; Gratz KF; Ruck P; Hunger M; Fuchs J
    Pediatr Hematol Oncol; 2005; 22(5):373-86. PubMed ID: 16020127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
    Malogolowkin MH; Katzenstein H; Krailo MD; Chen Z; Bowman L; Reynolds M; Finegold M; Greffe B; Rowland J; Newman K; Womer RB; London WB; Castleberry RP
    J Clin Oncol; 2006 Jun; 24(18):2879-84. PubMed ID: 16782927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.